Glen Eagle Advisors’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Glen Eagle Advisors’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-15	Closed	-$781	–	1030
2023 Q2	$781	Hold	15	–	–	﹤0.01%	977
2023 Q1	$813	Hold	15	–	–	﹤0.01%	969
2022 Q4	$866	Hold	15	–	–	﹤0.01%	1036
2022 Q3	$715	Hold	15	–	–	﹤0.01%	1000
2022 Q2	$726	Hold	15	–	–	﹤0.01%	922
2022 Q1	$930	Hold	15	–	–	﹤0.01%	875
2021 Q4	$1.22K	Buy	+15	New	+$1.28K	﹤0.01%	852

Other funds holding BIB

Cassaday & Co Wealth Management Mclean, Virginia $5.32B AUM 22.63% 1-Year Est. Return

CIC

Chase Investment Counsel Charlottesville, Virginia $474M AUM 95.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Capital Investment Advisors Atlanta, Georgia $7.59B AUM 23.38% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return

Jump Financial Chicago, Illinois $12.4B AUM 62.79% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

TCBWMS

Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return

Glen Eagle Advisors's BIB Position: Q3 2023 in Review

Glen Eagle Advisors sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2023, closing a stake of 15 shares — an estimated $781 sold.

Glen Eagle Advisors first reported a position in BIB in Q4 2021 and held it in 7 quarters. The position peaked at $1.22K in Q4 2021. 20 funds tracked by Wall St. Rank hold BIB as of Q3 2023.

Glen Eagle Advisors reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2023 after selling out during the quarter.
Glen Eagle Advisors sold 15 ProShares Ultra NASDAQ Biotechnology shares in Q3 2023, an estimated $781.
Glen Eagle Advisors first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2021 and held it in 7 quarters.
Glen Eagle Advisors's ProShares Ultra NASDAQ Biotechnology position peaked at $1.22K in Q4 2021.
20 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2023.

Based on Glen Eagle Advisors's 13F filing for Q3 2023, filed 13 Aug 2024.